Recovery Or Purification Patents (Class 435/239)
  • Patent number: 11946885
    Abstract: A method of using the relaxation rate (R1 and/or R2) of solvent NMR signal to noninvasively assess whether viral capsids in a capsid preparation are full or empty, and the percentage of full capsids if the vial contains a mixture of full and empty capsids. The method can simply, rapidly, and non-invasively prove the safety and potency of the capsid preparation and thus whether the capsid preparation can be approved for clinical use, without requiring any sample preparation or reagent addition.
    Type: Grant
    Filed: June 17, 2022
    Date of Patent: April 2, 2024
    Inventors: Yihua (Bruce) Yu, Marc Taraban
  • Patent number: 11773134
    Abstract: The present invention provides a process for the recovery and/or purification of a recombinantly expressed intracellular protein comprising the sequence of Annexin A5 (AnxA5) from an endotoxin-producing host cell with a cell wall, wherein the process comprises releasing the intracellular protein from the host cell, characterised in that the step of releasing the intracellular AnxA5 protein is conducted in the presence of a homogenisation buffer comprising non-ionic detergent, and preferably wherein the process does not include any centrifugation steps for the recovery and/or purification of the AnxA5 protein after its release from the host cell and/or in which the AnxA5 protein remains in solution throughout the process except when temporarily bound to any chromatographic resins.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: October 3, 2023
    Inventors: Toomas Moks, Jan Christoph Reich
  • Patent number: 11612648
    Abstract: A method for adapting an influenza virus to Vero cells is provided. The method comprises infecting Vero cells with the influenza virus, cultivating the infected Vero cells, harvesting influenza viruses of each passage, wherein infectious dose of the influenza viruses of one passage is greater than or equal to infectious dose of the influenza viruses of a previous passage. The present disclosure also relates to a composition. Said composition comprises polyriboinosinic acid-polyribocytidylic acid, at least one antibiotic or polyamide compound, at least one positive ion, influenza viruses and/or influenza antigens, wherein said influenza viruses and/or influenza antigens are acquired from Vero cell adapted influenza viruses.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: March 28, 2023
    Assignee: Yisheng Biopharma (Singapore) Pte Ltd
    Inventors: Yi Zhang, Yuhe Yan, Xu Zhang, Thomas Anthony Coton
  • Patent number: 11603527
    Abstract: The present invention relates to a method for purification of viral vectors, more closely it relates to purification of viral vectors from producer cells by using a single automated process. The method comprises the following steps: a) adding producer cells and cell lysis buffer to a processing container; b) mixing said producer cells and cell lysis buffer in said processing container to obtain a mixture; c) flowing said mixture through a chromatography column for purification of viral vectors, wherein the viral vectors are adsorbed on said chromatography column; and d) eluting viral vectors from the chromatography column into a product container.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: March 14, 2023
    Assignee: Global Life Sciences Solutions USA LLC
    Inventor: Trevor Smith
  • Patent number: 11472707
    Abstract: There is provided a method for manufacturing a bacterium-produced cellulose carbon having a sufficient specific surface area, and a high mechanical strength. The method manufactures a bacterium-produced cellulose carbon by carbonizing cellulose produced by thermally treating, and the method includes a cellulose forming step S1 of forming bacterium- produced cellulose whereby cellulose nanofibers are dispersed using a bacterium; an impregnating step S2 for impregnating the bacterium-produced cellulose with a supercritical fluid; a drying step S3 of vaporizing the supercritical fluid from the bacterium-produced cellulose containing the supercritical fluid and obtaining a dry product; and a carbonizing step S4 of heating and carbonizing the dry product in an atmosphere not causing combustion of the dry product.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: October 18, 2022
    Assignee: Nippon Telegraph and Telephone Corporation
    Inventors: Masaya Nohara, Shuhei Sakamoto, Mikayo Iwata, Masahiko Hayashi, Takeshi Komatsu
  • Patent number: 11292000
    Abstract: A variety of devices, systems, kits, and methods are provided for separating or enriching circulating tumor cells in a biological sample such as whole blood. In some aspects, the devices are multi-stage devices including at least a filtering stage, and two separation stages for ferrohydrodynamic separation of magnetically labelled white blood cells and for marker-independent and size-independent focusing of magnetically labeled particles so as to separate or enrich unlabeled rare cells in the biological sample. The devices and methods are, in some aspects, capable of high throughput in excess of 6 milliliters per hour while achieving high separation (>97%) of the unlabeled rare cells.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: April 5, 2022
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Leidong Mao, Yang Liu, Wujun Zhao
  • Patent number: 11286474
    Abstract: The invention relates to a process for the manufacturing and purification of recombinant enzyme products, in particular of food enzyme products and the use thereof. The invention particularly relates to a process for the processing of enzyme products from a microbial fermentation broth by methods of separation, enzymatic treatment and filtration procedures.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: March 29, 2022
    Assignee: C-LECTA GMBH
    Inventors: Stefan Schoenert, Mathias Salomo, Thomas Schultchen, Andreas Vogel, Sabrina Koepke, Sebastian Bartsch, Birgit Brucher, Claudia Feller
  • Patent number: 11254906
    Abstract: An automatic purification system using magnetic particles comprises: 1) a first container module; and 2) a system controller module. The first container module comprises a first container and a first magnetic field supply device disposed outside the first container. A first container liquid inlet is formed in the upper portion of the first container, and a first container liquid outlet is formed in the bottom of the first container. The system controller module can generate a variable magnetic field in the first container by controlling the first magnetic field supply device. A method for purifying a target component from a biological sample comprises a step for allowing a biological sample containing a target component to be in contact with magnetic particles capable of specifically binding the target component, in the first container in the automatic purification system.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: February 22, 2022
    Assignee: Nanjing GenScript Biotech Co., Ltd.
    Inventors: Xin Chen, Ruina He, Chao Wang, Hong Qian, Tao Bai
  • Patent number: 11118166
    Abstract: The present invention relates to modified avian eggs which can be used to produce increased levels of virus. The present invention also relates to methods of producing viruses in avian eggs of the invention, as well as the use of the viruses obtained to prepare vaccine compositions.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: September 14, 2021
    Assignees: University of Georgia Research Foundation, Inc.
    Inventors: Andrew Bean, John William Lowenthal, Luis Fernando Malaver-Ortega, Ralph A. Tripp
  • Patent number: 11103853
    Abstract: The present invention provides a process for recovering a viral product from a composition comprising said product and product-related impurities, which process comprises contacting the composition with a functionalised chromatography medium comprising one or more polymer nanofibres, wherein the viral product comprises a plurality of viruses, virus particles/virions, viral cores, membrane-stripped viruses, viral cores with outer membrane(s) removed and/or capsids removed, or proviruses, each of which contains one or more polynucleotides, and wherein the product-related impurities comprise a plurality of viruses, virus particles/virions, virus-like particles, viral cores, membrane-stripped viruses, viral cores with outer membrane(s) removed and/or capsids removed or proviruses, each of which is substantially devoid of polynucleotides.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: August 31, 2021
    Assignee: Puridify Ltd.
    Inventor: Ian Scanlon
  • Patent number: 11021689
    Abstract: The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising the steps of: a) performing a depth filtration of a starting material previously obtained from cells producing rAAV particles, the said starting material being selected in a group comprising a cell lysate and a culture supernatant, whereby a rAAV-containing clarified composition is provided; b) submitting the rAAV-containing clarified composition to an affinity purification step, whereby a first rAAV enriched composition is provided; c) submitting the first rAAV enriched composition at least once to: c1) a step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a salt gradient, preferably a linear salt gradient, and wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; or c2) a step of density gradient centrifugation, wherein the rAAV-containing fraction is collected, whereby a second rAAV e
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: June 1, 2021
    Inventor: Nicole Brument
  • Patent number: 10994007
    Abstract: Disclosed is an immunity inducer. The immunity inducer comprises virus like particles; the virus like particles comprise a virus-derived outer coat protein and an antigen-bound protein comprising an exogenous antigen; the outer coat protein constitutes an outer coat of the virus like particles, and the antigen-bound protein is comprised in the outer coat; and the virus like particles induce an immune effect of a living body on the antigen.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: May 4, 2021
    Assignees: Saitama Medical University, SYSMEX CORPORATION
    Inventors: Hiroshi Handa, Masaaki Kawano, Masahiko Kato
  • Patent number: 10982003
    Abstract: The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: April 20, 2021
    Assignee: Genentech, Inc.
    Inventors: Martin Gawlitzek, Shun Luo, Christina Teresa Bevilacqua
  • Patent number: 10967058
    Abstract: Compositions for prevention of Foot and Mouth Disease (FMD) are provided, comprising an antigen component in the amount equivalent to 0.5-20 ?g FMD virus and an adjuvant component comprising oil, an immunostimulatory oligonucleotide, and a polycationic carrier. Methods of using the composition, as well as the methods of reducing FMD persistence are also provided.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: April 6, 2021
    Assignees: Zoetis Services LLC, United States of America, as represented by the Secretary of Agriculture
    Inventors: Paul Joseph Dominowski, John Morgan Hardham, James Alan Jackson, Cyril Gerard Gay, Luis Leandro Rodriguez, Peter William Krug, Aida Elizabeth Rieder
  • Patent number: 10954493
    Abstract: Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero, MDCK or PER.C6 cell lines. The inventor has realised that the conditions used for influenza virus culture can increase the risk that pathogens other than influenza virus may grow in the cell lines and have identified specific contamination risks. Suitable tests can thus be performed during manufacture in order to ensure safety and avoid iatrogenic infections.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: March 23, 2021
    Assignee: Novartis AG
    Inventor: Jens-Peter Gregersen
  • Patent number: 10907133
    Abstract: The present invention relates to modified avian eggs which can be used to produce increased levels of virus. The present invention also relates to methods of producing viruses in avian eggs of the invention, as well as the use of the viruses obtained to prepare vaccine compositions.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: February 2, 2021
    Assignees: Commonwealth Scientific and Industrial Research Organisation, University of Georgia Research Foundation, Inc.
    Inventors: Andrew Bean, John William Lowenthal, Luis Fernando Malaver-Ortega, Ralph A. Tripp
  • Patent number: 10851349
    Abstract: A spiral tube countercurrent chromatography rotor for separating virus in a two part aqueous solvent is described.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: December 1, 2020
    Inventor: Martha Knight
  • Patent number: 10808227
    Abstract: Provided are a parvovirus derived from an unconcentrated cell culture supernatant, having a infectivity titer of 109 TCID50/mL or more and an {infectivity titer (TCID50/mL)}:{impurity protein concentration (ng/mL)} ratio more than 5000:1; and a method of producing such a high-infectivity titer and high-purity parvovirus.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: October 20, 2020
    Inventors: Yoshiyuki Sawamura, Koichiro Yanagida
  • Patent number: 10781459
    Abstract: Provided herein are methods related to co-packaging of multiple rAAV particles, e.g., by introducing multiple nucleic acid vectors encoding proteins or polypeptides or RNAs of interest into a single cell preparation.
    Type: Grant
    Filed: June 20, 2015
    Date of Patent: September 22, 2020
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Barry John Byrne, Phillip A. Doerfler, Nathalie Clement
  • Patent number: 10711237
    Abstract: Apparatus and methods for providing a single-use, disposable module or manifold for testing and analysis of bioprocesses. A module comprising a valve, a filter or guard column, an affinity column, and a flow cell is provided with several ports for receiving tubing connections for a sample and one or more solvents, as well as one or more outlet ports for connections to one or more waste reservoirs. The flow cell may use UV light to determine a protein concentration of a sample in one particular example. The module can be connected directly or indirectly to a bioreactor containing the bioprocess and material to be sampled, and can be disposed of once a production run has been completed. In addition, manifolds are provided which can be embodied as a valve assembly, and which can comprise the same components and features as the disposable module. The manifolds and modules are compact and easy to use. A portable device for use with a module is also provided.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: July 14, 2020
    Assignee: IDEX Health & Science LLC
    Inventors: Victor Simonyi, Darrin Kurt Pickle, James Smyth, Craig Love
  • Patent number: 10662237
    Abstract: The present invention relates to the field of protein purification. In particular, the invention concerns methods for increasing the filtration capacity of virus filters, by combined use of endotoxin removal and cation-exchange media in the prefiltration process.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: May 26, 2020
    Assignee: Genentech, Inc.
    Inventor: Amit Mehta
  • Patent number: 10626379
    Abstract: The present invention relates to methods of replicating viruses in vitro. In particular, the invention relates to a genetically modified population of cells, and/or a population of cells treated with an exogenous compound, wherein the cells are capable of producing more virus than cells lacking the genetic modification and/or lacking treatment with the exogenous compound. The invention also relates to methods of producing populations of such cells, as well as the use of the viruses obtained to prepare vaccine compositions.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: April 21, 2020
    Assignees: Commonwealth Scientific and Industrial Research Organisation, University of Georgia Research Foundation, Inc.
    Inventors: Andrew Bean, John William Lowenthal, Luis Fernando Malaver-Ortega, Ralph A. Tripp
  • Patent number: 10570376
    Abstract: A process for the purification of influenza virus or derivative thereof requires providing a source of influenza virus or derivative thereof, optionally subjecting the source to a pre-purification step, followed by subjecting the source to at least one chromatographic step on chromatographic material selected from the group consisting of porous particles having mean pore sizes of at least 20 nm, perfusion particles, gel-in-a-shell particles, tentacle like particles, membrane adsorbers, and monoliths, and collecting fractions eluted from the chromatographic material that contain the influenza virus or derivative thereof, excluding sulfuric ester of cellulose or cross-linked polysaccharides.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: February 25, 2020
    Inventors: Matjaz Peterka, Ales Strancar, Marko Banjac, Petra Kramberger, Elisabeth Roethl, Thomas Muster
  • Patent number: 10329536
    Abstract: The present invention concerns a method for production of an active ingredient of a drug or diagnostic agent, in which (a) MDCK cells are infected with a virus; and (b) the MDCK cells are cultured in suspension culture on a commercial scale under conditions that permit multiplication of the viruses; in which culturing occurs in a volume of at least 30 L. The invention also concerns a method for production of a drug or diagnostic agent in which an active ingredient is produced according to the above method and mixed with an appropriate adjuvant, auxiliary, buffer, diluent or drug carrier.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: June 25, 2019
    Assignee: Seqirus UK Limited
    Inventors: Jürgen Vorlop, Christian Frech, Holger Lübben, Jens-Peter Gregersen
  • Patent number: 10294460
    Abstract: The disclosure provides methods for poliovirus purification from crude cell culture harvests using a detergent followed by a clarification step.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: May 21, 2019
    Inventors: Mariken Segers, Beckley Kungah Nfor, Feras Nachmi Alazi, Marcel Leo De Vocht
  • Patent number: 10160956
    Abstract: The proposed method facilitates the single-stage and at the same time effective purification of phage preparations for therapeutic uses, and facilitates the maintenance of bacteriophage antibacterial activity both in the case of displacement of the bacteriophage from the resin and its proteolytic release. The protein modification of the phage capsid with appropriate binding motifs makes it possible to purify therapeutically bacteriophage strains using affinity chromatography. The proposed method is useful in the display of selected polypeptided on a bacteriophage capsid without the need to genetically modify the bacteriophage, and thus makes it possible to produce phage preparations for various uses using wild-type phages occurring naturally or others not additionally modified for phage-display purposes.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: December 25, 2018
    Inventors: Krystyna Dabrowska, Anna Oslizlo, Paulina Budynek, Agnieszka Otrowicz, Andrzej Gorski, Grzegorz Figura, Barbara Owczarek, Agnieszka Kopciuch
  • Patent number: 10101262
    Abstract: A method for evaluating a biological material for unassociated virus-size particles having a particular epitope indicative of an adeno-associated virus viral type or an adenovirus viral type uses a fluorescent antibody stain specific for binding with the epitope and a fluid sample with the virus-size particles and fluorescent antibody stain is subjected to flow cytometry with identification of fluorescent emission detection events indicative of passage through a flow cell of a flow cytometer of unassociated labeled particles of virus size including such a virus-size particle and fluorescent antibody stain.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: October 16, 2018
    Assignee: IntelliCyt Corporation
    Inventors: Michael A. Artinger, Francis Kevin Kohlmeier, Michael W. Olszowy, Tyler Donald Gates
  • Patent number: 10087423
    Abstract: The present invention provides methods and systems for recovering an essentially cell-associated expression product from a host cell comprising (a) culturing said host cell under conditions that allow expression of said expression product; (b) collecting said host cell in/on a filter unit; (c) disrupting said host cell in/on the filter unit; and (d) separating said expression product from said disrupted host cell. The present invention also provides an expression product obtainable by the methods or systems, wherein the expression product is a poxvirus.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: October 2, 2018
    Inventors: Engelbert Wehnes, Uwe Werner, Christian Leschke
  • Patent number: 10076565
    Abstract: An aspect of the present invention is directed towards DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient. The DNA plasmid is capable of expressing a consensus influenza antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, wherein the consensus influenza antigen comprises consensus hemagglutinin (HA), neuraminidase (NA), matrix protein, nucleoprotein, M2 ectodomain-nucleo-protein (M2e-NP), or a combination thereof. Preferably the consensus influenza antigen comprises HA, NA, M2e-NP, or a combination thereof. The DNA plasmid comprises a promoter operably linked to a coding sequence that encodes the consensus influenza antigen. Additionally, an aspect of the present invention includes methods of eliciting an immune response against a plurality of influenza virus subtypes in a mammal using the DNA plasmid vaccines provided.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: September 18, 2018
    Inventors: Ruxandra Draghia-Akli, David B. Weiner, Jian Yan, Dominick Laddy
  • Patent number: 10072250
    Abstract: The present invention provides a method for efficiently manufacturing a non-enveloped virus with high purity without laborious operation by cultivating cells having the ability to produce a non-enveloped virus and bringing the cells and an acidic solution into contact with each other. A non-enveloped virus vector manufactured by the method of the present invention and a composition having the non-enveloped viral vector as an active ingredient are very useful as gene transfer methods in the fields of basic research and clinical application gene therapy.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: September 11, 2018
    Assignee: TAKARA BIO INC.
    Inventors: Shuhei Sakamoto, Yasuhiro Kawano, Katsuyuki Dodo, Tatsuji Enoki, Hirofumi Yoshioka, Hikaru Takakura, Junichi Mineno
  • Patent number: 10041049
    Abstract: The invention provides methods for large-scale production of recombinant adenovirus 35, using perfusion systems and infection at very high-cell densities.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: August 7, 2018
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Alfred Luitjens, John A. Lewis
  • Patent number: 10036747
    Abstract: The invention relates to dimeric proteins comprised of subunits having (i) recombinant lamprey variable lymphocyte receptor (VLR) diversity regions linked to (ii) multimerization domains. The dimeric proteins exhibit binding specificity for glycosylated antigens, and they may be used in methods of detecting or isolating glycans from a sample, and in methods of disease diagnosis, prognosis, progression monitoring, treatment, and imaging.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: July 31, 2018
    Inventors: Zeev Pancer, Li Mao, Xia Hong, Mark Z. Ma
  • Patent number: 9809639
    Abstract: Materials and methods for use of constrained cohydration agents in the purification of biological materials such as antibodies, viruses, cells, and cellular organelles in connection with convective chromatography, fluidized bed or co-precipitation applications.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: November 7, 2017
    Inventor: Peter Stanley Gagnon
  • Patent number: 9610352
    Abstract: Provided herein are lyophilized viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The lyophilized viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: April 4, 2017
    Assignee: Oncolytics Biotech Inc.
    Inventors: Matthew C. Coffey, Sarah Serl, Leo Pavliv
  • Patent number: 9574181
    Abstract: Methods for producing reassortant viruses are provided wherein the transcription and/or translation of the hemagglutinin and/or neuraminidase genes are suppressed.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: February 21, 2017
    Assignee: Seqirus UK Limited
    Inventors: Heidi Trusheim, Peter Mason, Michael Franti, Björn Keiner, Melissa Sackal, Juerg Hunziker, David Morrissey, François Jean-Charles Natt
  • Patent number: 9528126
    Abstract: Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: December 27, 2016
    Assignee: Genzyme Corporation
    Inventors: Guang Qu, John Fraser Wright
  • Patent number: 9492840
    Abstract: A method for removing an organic ligand from a surface of a particle including: obtaining a particle having an organic ligand disposed on a surface thereof; contacting the particle with an alkylammonium salt represented by Chemical Formula 1: NR?4+A???Chemical Formula 1 wherein groups R? are the same or different and are each independently hydrogen or a C1 to C20 alkyl group, provided that at least one group R? is an alkyl group, and A is a hydroxide anion, a halide anion, a borohydride anion, a nitrate anion, a phosphate anion, or a sulfate anion; and heat-treating the particle to carry out a reaction between the alkylammonium salt and the organic ligand.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: November 15, 2016
    Inventors: Seung Yeon Lee, Jun Ho Lee, Kyungsang Cho, Young Suk Jung
  • Patent number: 9464281
    Abstract: A method for concentrating viruses includes applying a magnetic force to a mixture containing: sugar chain-immobilized magnetic metal nano-particles each having a structure in which a sugar chain-immobilized metal nano-particle is bound to a first magnetic nano-particle; second magnetic particles with mean particle size larger than that of the sugar chain-immobilized magnetic metal nano-particles; and a specimen. Each sugar chain-immobilized metal nano-particle has a structure where a ligand-conjugate is bound to a metal nano-particle via sulfur atoms. The ligand-conjugate has a structure where a linker compound's amino group is connected to a sugar chain having a reducing terminal. The linker compound includes, in molecules thereof, an amino group, sulfur atoms, and a hydrocarbon chain having carbon-nitrogen bonds.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: October 11, 2016
    Assignees: SUDx-Biotec Corporation, National University Corporation Kagoshima University, Neat Co., Ltd.
    Inventors: Yasuo Suda, Masahiro Wakao, Takashi Kodama
  • Patent number: 9295702
    Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: March 29, 2016
    Assignee: Transgene S.A.
    Inventors: Daniel Malarme, Yves Cordier, Claude Sene
  • Patent number: 9233912
    Abstract: The invention in some aspects relates to devices and methods for nucleating crystals under controlled conditions. In some aspects of the invention, devices and methods are provided for continuous crystallization.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: January 12, 2016
    Assignee: Massachusetts Institute of Technology
    Inventors: Allan Stuart Myerson, Shin Yee Wong
  • Patent number: 9182395
    Abstract: This invention relates to an assay device and a method for pretreating a specimen containing a biologically-relevant substance and then assaying the biologically-relevant substance. Biologically-relevant substances used in the assay method include microorganisms, cells, viruses, nucleic acids, polysaccharides, proteins (including antigens, antibodies, chromoproteins, and enzymes), peptides, nucleic acids, and small molecules. This pretreatment method removes contaminants from the biologically-relevant substances using supports such as magnetic particles, gels, resins, membranes, and solid-phased reagents. Therefore, in the assay method the following steps are generally carried out (i) a pretreatment step of treating a specimen using one or more first supports and then one or more second supports, and (ii) the assay step carried out after the pretreatment step. In particular, the pretreatment method reduces false positives and false negatives in the assay.
    Type: Grant
    Filed: December 25, 2009
    Date of Patent: November 10, 2015
    Inventor: Hideji Tajima
  • Patent number: 9175052
    Abstract: The disclosure describes methods for the purification of protein-enriched extracts to provide concentrates and isolates and methods for incorporation of such materials into products. The purification methods are adapted for removal of one or more of ash, metal salts, alkaloids, particulates, heavy metals, and other impurities and/or contaminants from extracts, as well as modifying the sensory characteristics (e.g., odor, color, and/or taste characteristics) of extracts. The methods generally include diafiltration, treatment with functionalized resins, and supercritical extraction. A protein composition in the form of a concentrate or isolate is provided, the protein composition including RuBisCO, F2 fraction proteins, or combination thereof extracted from a plant of the Nicotiana species, wherein the protein composition is characterized by one or more of: an ash content of less than about 15% by weight; a nicotine content of less than about 10 ?g/g; and a heavy metal content of less than about 60 ?g/g.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: November 3, 2015
    Assignee: R.J. Reynolds Tobacco Company
    Inventors: Anthony Richard Gerardi, Crystal Dawn Hege Byrd, Thaddeus Jude Jackson, Chelsea Allison Betts, John-Paul Mua, Kyle Ford
  • Patent number: 9173989
    Abstract: The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein/and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: November 3, 2015
    Inventors: Olle Larm, Tomas Bergström
  • Patent number: 9169491
    Abstract: A process for producing a retroviral or lentiviral vector formulation comprising a filter-sterilization step wherein the filter-sterilization step is not the final step in the purification process.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: October 27, 2015
    Assignee: Oxford BioMedica (UK) Limited
    Inventors: Richard Truran, Robert Buckley, Pippa Radcliffe, James Miskin, Kyriacos Mitrophanous
  • Patent number: 9109201
    Abstract: The present invention relates to methods for purification of Vaccinia viruses (VV) and/or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: August 18, 2015
    Assignees: Bavarian Nordic A/S, Otto-von-Guericke-Universität, Sartorius Stedim Biotech GmbH
    Inventors: Sara Post Hansen, Rene Faber, Udo Reichl, Michael Wolff, Anders Peter Gram
  • Patent number: 9085753
    Abstract: The present invention provides novel serum-free cell culture medium and methods for cultivating MDCK cells. In particular, non-tumorigenic MDCK cells. The present invention also provides methods for producing influenza viruses (e.g., particularly cold-adapted, and/or temperature sensitive, and/or attenuated influenza viruses) that eliminate the need for a cell culture medium exchange step. The novel medium and methods are useful to grow influenza viruses, in cell culture to high titer. The present invention further provides purification methods for purifying influenza viruses with high overall recovery of live virus and result in levels of host cell DNA (HCD), host cell protein (HCP) and non-specific endonuclease (e.g., Benzonase), which are below the specifications required by regulatory agencies. The immunogenic compositions can be used to actively immunize subjects or to generate antibodies for a variety of uses, including passive immunization and diagnostic immunoassays.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: July 21, 2015
    Assignee: MEDIMMUNE, LLC
    Inventors: Jonathan Liu, Mark Thompson, Luis J. Maranga, Floro Cataniag, Simon S. Hsu
  • Patent number: 9051542
    Abstract: Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. ?˜500 mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4×1013 vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic® F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: June 9, 2015
    Assignee: Genzyme Corporation
    Inventors: John Fraser Wright, Guang Qu
  • Patent number: 9045777
    Abstract: The present invention relates to a pol I promoter derived from Vero cells and a recombinant vector containing the same. When the pol I promoter derived from Vero cells according to the present invention is utilized, viruses can be manufactured efficiently, and consequently, the manufacture of both seasonal influenza vaccine and pandemic vaccine can be prepared more quickly to usefully address either situation.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: June 2, 2015
    Assignees: Korea Center for Disease Control and Prevention, Chungbuk National University Industry-Academic Cooperation Foundation
    Inventors: Young Ki Choi, Chun Kang, Kee Jong Hong, Min Suk Song, Yun Hee Baek
  • Patent number: 9028839
    Abstract: The invention relates to a vaccine composition comprising: a) inactivated whole virus, and b) a stabilizing excipient which comprises: i. a buffer solution, ii. a mixture of essential and nonessential amino acids, iii. a disaccharide, iv. a polyol, v. a chelating agent, vi. urea or a urea derivative, and vii. a nonionic surfactant.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: May 12, 2015
    Assignee: Sanofi Pasteur S.A.
    Inventors: Alain Francon, Michel Chevalier, Nadege Moreno, Eric Calvosa, Sandrine Cigarini, Virginie Fabre
  • Publication number: 20150125929
    Abstract: The present invention relates to novel and improved methods for the purification of biomolecules. In particular, the present invention relates to methods of protein purification which employ a porous solid support modified with a charged fluorocarbon composition.
    Type: Application
    Filed: March 18, 2013
    Publication date: May 7, 2015
    Inventors: Mikhail Kozlov, Wilson Moya, Jad Jaber, William Cataldo, Ajish Potty, Christopher Gillespie